Clinical observation of Thalidomide combined with percutaneous cryoablation on treating advanced primary liver cancer

Liu Tao,Mi Yan-jun,Zhang Ya-ya,Qiu Guo-qin,Guo Chun-hua,Lin Zhi-cai
DOI: https://doi.org/10.3969/j.issn.1671-3826.2013.04.10
2013-01-01
Abstract:Objective To explore the efficacy and the adverse effects of Thalidomide(TLD) in treatment of advanced primary liver cancer after percutaneous cryoablation(PTC).Methods Fifty patients with advanced primary liver cancer were divided into trial group and control group(n = 25 / group) at random.The trial group was treated with oral TLD after PTC,and the control group was treated with PTC alone.Results The overall response rate of the trial group was 88.0%,with complete remission(CR) in 2,partial remission(PR) in 20,no change(NC) in 2 and progressive development(PD) in 1 patient(s),and that of the control group was 56%,with CR in 1,PR in 13,NC in 5 and PD 6 patients(P < 0.05).Adverse effects were less and tolerated.According to the follow-up up to 3 years,the 1-,2-and 3-year survival rate of the trial group was 80%,64% and 44%,and that of control group was 48%,32% and 16%,respectively(P < 0.05).Conclusion Treatment of TLD combined with PTC can prolong the survival time of advanced primary liver cancer patients with less adverse effects.
What problem does this paper attempt to address?